BICDL1

Across TCGA pan-cancer cohorts, BICDL1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BICDL1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BICDL1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BICDL1 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where BICDL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BICDL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+1.590	.004	6	view →
CCRCC	Male	II,III,IV	−0.421	<.001	6	view →
LSCC	Female	All	−0.710	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

BICDL1–HNSC

Open the HNSC breakdown →